S
PRINT (Systolic Pressure Intervention Trial) studied whether treatment to a systolic blood pressure (SBP) goal of <120 mm Hg (intensive treatment) was superior to an SBP treatment goal of <140 mm Hg (standard treatment) in adults without diabetes mellitus who were ≥50 years of age at high risk for cardiovascular events. 1 In this issue of Circulation, Bress and colleagues 2 project the impact of implementation of the intensive strategy on all-cause mortality and serious adverse events (SAEs) in the US population. Implementing intensive treatment, with estimated improvements in mortality despite increases in SAEs, needs to be framed within the rapidly changing healthcare payment and delivery models in the United States. 3 Two acts of Congress, the Patient Protection and Affordable Care Act of 2010 and the Medicare Access and CHIP Reauthorization Act of 2015, 4 dramatically shifted the focus of healthcare delivery from fee-for-service to a value-based model with an underpinning that is patient-centered coordination of care. 3 Regardless of the fate of the Patient Protection and Affordable Care Act, trends in health care put into motion by this legislation will continue. With the Medicare Access and CHIP Reauthorization Act, the Centers for Medicare & Medicaid Services gained critical tools to support its goal to link 50% of fee-for-service payments by 2018 to alternative payment and population-based care models such as accountable care organizations and patientcentered medical homes. Including growth in the private health insurance market, upward of 70 million people in the United States may be covered through these alternative payment models by 2020 and 150 million by 2025. 5 These forces will affect hypertension management. Strong evidence suggests that team-based, coordinated care with shared decision making improves outcomes and reduces costs, particularly for hypertension. 6, 7 Coupled with current growth trends in population-based health initiatives, the United States is positioned to realize the benefits of intensive treatment for hypertension. 8 To understand the potential impact of achieving SPRINT intensive treatment goals in the US population, Bress and colleagues 2 identified a cohort of 2185 NHANES (National Health and Nutritional Examination Survey) "SPRINT-eligible" participants who met the inclusion and exclusion criteria of the SPRINT trial. They estimate that if the intensive SBP goal of <120 mm Hg were implemented in SPRINT-eligible adults in the United States, 107 500 deaths could be averted annually. The majority of averted deaths, 67 300 per year, occur in those ≥75 years of age because of the high event rate in this group. Intensive treatment is projected to prevent 32 700 deaths annually among those with chronic kidney disease and to prevent 46 100 cases of heart failure. The downside of intensive treatment compared with an SBP goal of <140 mm Hg is that there would be incremental incidence of SAEs, including 56 100 episodes of hypotension, 34 400 episodes of syncope, 43 400 episodes Hypertension Treatment and Outcomes in the Era of Population Health, Coordinated Care, and Medicare Access and CHIP Reauthorization Act (MACRA) of electrolyte abnormalities, and 88 700 cases of acute renal injury or acute renal failure, corresponding to an annual increased risk for these events of 0.31%, 0.19%, 0.24%, and 0.49%, respectively.
There are some differences in the NHANES and SPRINT populations that might modify projections or applicability of these results. SPRINT excluded 2.5% of potentially eligible participants because of standing SBP <110 mm Hg after 1 minute. Because standing BP was not measured, NHANES includes this group; hence, projections would likely lead to an underestimation of hypotension and syncope among an intensively treated US population unless they were similarly screened. SPRINT may have been slightly enriched for a population that included those with subclinical CVD as determined by a coronary artery calcium score, anklebrachial index ≤0.90, or evidence of left ventricular hypertrophy. Alternatively, as is typical for clinical trials, SPRINT may have recruited a population that was healthier and more adherent to medication. This could cut both ways because it might underestimate the beneficial effect in a larger, sicker population but overestimate medication-related side effects because of higher adherence in SPRINT and perhaps a bias toward reporting SAEs in the intensively treated group. 9 Finally, SPRINT patients benefitted from the close follow-up and team-based coordination mandated by the trial, including being seen monthly for the first 3 months and every 3 months thereafter. Settings such as patient-centered medical homes are organized to facilitate this level of management. 10 Differences in BP measurement between SPRINT and NHANES could reduce the impact on mortality. BP in SPRINT was measured with an automatic oscillometric monitor that was programmed to take 3 consecutive seated BPs after 5 minutes of sitting, an approach that generally yields an SBP that is 7 to 10 mm Hg lower than the methodology in NHANES, in which BP was measured by a trained study physician using a mercury sphygmomanometer. 11 If and when SPRINT results are translated from the clinical trial to everyday practice, it will be important to take into account that a "SPRINTequivalent" office BP measurement will most likely be 10 mm Hg higher than those obtained by the methodology in SPRINT. 11 Therefore, an office SBP goal of <120 mm Hg would be too aggressive, and an office SBP goal of <130 mm Hg would be appropriate and reflect the real-life application of SPRINT results. Recognizing this potential, the authors conducted analysis among NHANES participants who met the SPRINT eligibility criteria, as well as those with a 10-and 20-mm Hg higher SBP criteria. 2 This reduced the SPRINT-eligible US adult pool of patients from 18.1 million to 12.8 million and 8.3 million, respectively. In this analysis, the potential benefit of 107 500 lives saved annually by intensive treatment is reduced to 84 000 and 62 700, respectively.
In SPRINT, although the trend was favorable, there was no significant benefit of intensive treatment for allcause mortality reduction in women, blacks, those with coronary heart disease, or those with chronic kidney disease. 1 Nevertheless, using the NHANES data, the authors applied the overall SPRINT observed mortality reduction of 27% to these subgroups and estimated that deaths prevented for women would be 41 100; for blacks, 8800; for those with coronary heart disease, 19 700; and for those with chronic kidney disease, 32 700. Is it reasonable to apply this estimate to subgroups who did not achieve significance in SPRINT? The answer is yes because in SPRINT "there were no significant interactions between treatment and subgroup with respect to the primary outcome or death from any cause."
1 Therefore, it can be reasonably assumed that the entire US population would be adequately powered so that the point estimate for mortality reduction would apply to these subgroups.
On a population basis, it is difficult to ignore such significant benefits and such an increase in SAEs from adopting the intensive treatment strategy. As the authors point out, treating SPRINT-eligible patients to the intensive goal could account for a 20% reduction in cardiovascular deaths in the US population. At the same time, the increase in SAEs warrants an aggressive effort to identify those who might achieve the greatest benefit and least risk for harm. Perhaps there are subgroups in SPRINT who can be identified who had especially great benefit with low number needed to treat and acceptable number needed to harm. For example, in the AASK trial (African American Study of Kidney Disease and Hypertension), those with greater visit-to-visit variability had higher all-cause and cardiovascular-associated mortality, as well as increased cardiovascular and renal events. 12 Perhaps in SPRINT-eligible patients with greater visit-tovisit variability, the benefits of intensive treatment would greatly outweigh the risk of SAEs.
Implementation of an intensive treatment goal faces significant headwinds for adults ≥60 years of age. Because SPRINT is the only trial that supports intensive SBP reduction to a goal of <120 mm Hg in older adults without diabetes mellitus, a recent systematic review 13 suggested that there is only low-to moderate-strength evidence that a target of ≤140/85 mm Hg is beneficial in this age group. On the basis of this suggestion, the American College of Physicians/American Academy of Family Physicians recommended a goal of <150 mm Hg for adults ≥60 years of age and gave only a grade of "weak recommendation, low-quality evidence" for a goal of <140 mm Hg in those ≥60 or years of age at high cardiovascular risk. 14 Debate about hypertension treatment goals may divert attention from the fact that despite decades of efforts hypertension is still undertreated. There are an estimated 29.2 million adults in the United States be-tween the ages of 60 and 79 with SBP >150 mm Hg. 15 These individuals do not meet the treatments goals of the American College of Physicians/American Academy of Family Physicians 14 or any other current guideline. Large-scale efforts with appropriate resource allocation should begin with these undertreated populations. Proven approaches to ensure adequate access to health care and appropriate follow-up are of paramount importance. Organizations that care for patients in a patientcentered medical home delivery model such as Kaiser Permanente can address these issues and achieve 80% BP control. 10 The hope is that the provocative potential national mortality benefits of the present study will stimulate renewed and reinvigorated efforts to achieve more effective BP control. Through enhanced coordination of care provided by accountable care organizations and patient-centered medical homes that will be encouraged by the Medicare Access and CHIP Reauthorization Act, effective hypertension management will lead to lower hypertension-associated mortality and fewer SAEs. 
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